| |
|
|
|
Board of Directors
|
| Management Team
|
|
Scientific Advisory Board
|
|
Business Advisory Board
|
| InVivo’s Board of Directors |
| Frank Reynolds, Chairman of the Board and CEO |
Mr. Reynolds leads our teams to commercialize our novel neurological science and technologies that were developed at Massachusetts Institute of Technology and Harvard Medical School.
Prior to joining InVivo Therapeutics, Mr. Reynolds was Director, Global Business Development for Siemens Corporation were he was responsible for new business revenue in 132 countries. At Siemens, Frank won numerous awards including the 2005 Global Presidential Sales Award, and he was a 2004 Top+ USA Strategy Award winner for his initiatives in global sales force strategy and collaboration. Mr. Reynolds was Founder and CEO of Expand The Knowledge, Inc from 1997-2002. In addition, Mr. Reynolds has 10 years management experience primarily in healthcare related fields.
Mr. Reynolds won the prestigious “Top 40 Irish-American Executive Award” from the Irish-Echo the largest Ireland focused publication in the world. Mr. Reynolds has been an Executive Board Member of the Ireland Chamber of Commerce of the United States since 1998. He is a graduate of the Sloan Fellows Program at the Massachusetts Institute of Technology where he completed his MBA and coursework at the Harvard Business School. His graduate school education includes a M.S. in Technology Management Program from The Wharton School of Business and a M.S. in Engineering from the University of Pennsylvania, a Masters in Health Administration from Saint Joseph University, a M.S. in Management Information Systems from Temple University, a M.S. in Psychology from Chestnut Hill College, and he received his Bachelors of Science in Marketing from Rider University. |
Go To Top |
| Richard Roberts, PhD: 1993 Nobel Laureate in Medicine and Physics; Scientific Advisory Board |
Dr. Roberts won the 1993 Nobel prize in Medicine and Physiology
Dr. Richard J. Roberts is the Chief Scientific Officer at New England
Biolabs, Beverly, Massachusetts. He was educated in England, attending
St. Stephen'ss School and the City of Bath Boys' School in Bath before
moving to the University of Sheffield where he obtained a B.Sc. in
Chemistry in 1965 and a Ph.D. in Organic Chemistry in 1968. His
postdoctoral research was carried out in Professor J.L. Strominger's
laboratory at Harvard, where he studied the tRNAs that are involved in
the biosynthesis of bacterial cell walls. From 1972 to 1992, he worked
at Cold Spring Harbor Laboratory, reaching the position of Assistant
Director for Research under Dr. J.D. Watson.
He
began work on the newly discovered Type II restriction enzymes in 1972
and in the next few years more than 100 such enzymes were discovered
and characterized in Dr. Roberts' laboratory. His laboratory has cloned
the genes for several restriction enzymes and their cognate methylases
and studies of these enzymes has been a major research theme. Dr.
Roberts has also been involved in studies of Adenovirus-2 beginning
with studies of transcription that led to the discovery of split genes
and mRNA splicing in 1977. This was followed by efforts to deduce the
DNA sequence of the Adenovirus-2 genome and a complete sequence of
35,937 nucleotides was obtained. This latter project required the
extensive use of computer methods, both for the assembly of the
sequence and its subsequent analysis. His laboratory pioneered the
application of computers in this area and the further development of
computer methods of protein and nucleic acid sequence analysis
continues to be a major research focus. The field of DNA
methyltransferases is also an area of active research interest and
crystal structures for the HhaI methyltransferase both alone and in
complex with DNA have been obtained in collaboration with Dr. X. Cheng.
The latter complex is quite remarkable as the protein causes the target
cytosine base to flip completely out of the helix so that it is
clear that there are many more restriction enzyme
genes in Nature than had been previously suspected.
|
| Go To Top |
| Christi Pedra, CEO Siements Hearing Instruments, Inc. |
Christi M. Pedra, President and CEO of Siemens Hearing Instruments, took the reigns of one of the largest hearing instrument manufacturers in January 2007. She is charged with leading the company's sales, manufacturing, product development, customer relations and research and development in the United States.
Pedra, no novice to Siemens, has been with the organization for over 20 years. Most recently she helped launch Siemens One as Vice President of Executive Relations and was promoted to Vice President of Sales and Chief Operating Officer in 2004. In this role Pedra served as the lead sales executive for Siemens One, responsible for regional business development and vertical markets outside the public sector. Pedra was also responsible for the Siemens One sales strategy and was charged with managing the people and processes needed to accomplish the sales plan.
Prior to her role with Siemens One, Pedra served as Vice President of Executive Relations for Siemens Corporation in the Office of the President. While with Siemens Corporation, she was responsible for business development activity as part of the Siemens top+ US Business Initiatives. Pedra also facilitated executive-level customer relationships within corporations and government agencies.
Pedra is a member of the advisory committee for the Women's Information Network at Siemens. In 2001, she was appointed to the Siemens ICN Executive Council on Diversity.
Pedra participates in leadership activities in both the business and civic sectors. Currently, Pedra is a member of the National Collegiate Athletic Association Leadership Advisory Board. She also serves on the National Council for Liberal Education America'ss Promise and takes part in several formal and informal mentoring programs. Pedra is involved with NYC's task force on stimulating economic growth. And in 2002, Pedra was nominated and selected to be a David Rockefeller Fellow, a one-year leadership program sponsored by the NYC Partnership and the David Rockefeller Foundation.
|
| Go To Top |
| InVivo’s Management Team |
| Frank Reynolds, Founder, Chairman of the Board and CEO |
| Eric Woodard, MD- Chief Medical Officer |
Dr. Woodard, MD is Chief, Neurosurgery at New England Baptist Hospital in Boston. Dr. Eric Woodard received his medical degree from the Pennsylvania State University and completed his residency in Neurological surgery at Emory University. Following residency Dr. Woodard completed a fellowship in complex spinal surgery at the Medical College of Wisconsin under Dr. Sanford Larsen. He is a diplomat of the American Board of Neurological Surgeons.
Dr. Woodard was formerly Chief of the Division of Spinal Surgery in the Department of Neurological Surgery at Brigham and Women’s Hospital, where he held the rank of Assistant Professor in Surgery at Harvard Medical School.
Since joining the medicals staff in 2004 Dr. Woodard has continued to practice complex spinal surgery and has established the Neurosurgery Fellowship in spinal surgery at New England Baptist Hospital. He has been an editorial board member for The Journal of Spinal Disorders, Spine Universe.com and is an ad hoc reviewer for Neurosurgery, Journal of Neurosurgery and the New England Journal of Medicine.
Dr. Woodard is a member numerous professional societies and organizations that include the American Association of Neurological Surgeons, the Congress of Neurological Surgeons, the Joint Section of the AANS/CNS, Spine and Peripheral Nerve, AO Spine North America, the North American Spine Society, Massachusetts Medical Society, and the Racchidian Society. He is the immediate past- chairman of the AO Spine North America Board and serves on the Board of AO Spine International.
Dr. Woodard has published many articles and book chapters in the field of spine surgery and lectures extensively both nationally and internationally. He lives in Boston with his wife and children.
|
| Go To Top |
|
Christopher Pritchard, Director R&D |
Christopher Pritchard is responsible for product development and manufacturing of InVivo’s multi-disciplinary platform technologies. In developing truly innovative technologies InVivo does not have comparative technologies that can provide a roadmap for product development or manufacturing. InVivo relies on Christopher to harness the resources of MIT, Harvard, and industry to bring our treatment for spinal cord injuries and spinal cord tumors to market.
As part of MIT’s Langer Lab Christopher is a candidate for a Ph.D. from MIT in the Department of Chemical Engineering and an MBA from the MIT-Sloan School of Management. Christopher is the key collaborator with Neuroscientists from Harvard’s Brigham and Women’s Department of Neurosurgery including Teng Lab.
Christopher received his Masters in Engineering Science from the University of Oxford with First Class Honours. At Oxford, he ranked second in his class, was awarded the Edgell Sheppee Prize for Excellent Performance. Before joining InVivo, Christopher also spent a year at Princeton University, where he won an award for his research. He holds an Engineering Leadership Award from the Royal Academy of Engineering. |
Go To Top |
|
John Baker, Chief Information Officer
|
John Baker's career spans over twenty years including the founding of Performance Analytics, LCC an IT consulting company focused on Life Science companies and specializing in leveraging analytics to reduce IT costs using cloud computing to efficiently manage their IT infrastructure.
He has extensive experience in all areas of information technology. His roles have been wide ranging including executive and management positions in applications development, customized tools development, global network design, network operations centers, data center design and implementation, server consolidation, databases design and development, web-based application systems, data and communications systems, and end user support systems.
At Global Crossing for almost 10 years John was the recipient of numerous executive level awards. John founded Global Crossing's International Information Technology Efficiency Group and won awards for eliminating millions of dollars per year in operations expenses.
John is a graduate of Massachusetts Institute of Technology, where he earned his Masters of Science in Engineering and Management: Systems Design and Management. In addition, John graduated magna cum laude with a dual degree in Bachelor of Science in Computer Science and Bachelor of Arts in Mathematics from Hawaii Pacific University.
John Baker was honorably discharged from the United States Navy after serving in the Persian Gulf.
|
Go To Top |
|
Robin Newman, Director Clinical and Regulatory Affairs
|
Robin W. Newman, RN, MSN, CPNP, CCRA, RAC before joining InVivo Therapeutics Corporation, Robin was a co-founder and former Chief Scientific Officer of MedTrials, Inc., a clinical research consulting firm headquartered in Dallas, Texas. Throughout her 20-year career in clinical research, Robin has worked in the roles of clinical research coordinator, clinical research associate, senior research associate, senior consultant and executive manager. Her clinical specialties are medical device, cardiology, pediatrics and surgery. Robin received her BSN from the University of Texas at Austin, and her MSN from the University of Texas at Arlington. She is certified as a Pediatric Nurse Practitioner through The National Association of Pediatric Nurse Associates and Practitioners (NAPNAP), a Certified Clinical Research Associate and Credentialed Clinical Research Trainer through the Association of Clinical Research Professionals (ACRP), Regulatory Affairs Certified through the Regulatory Affairs Professional Society (RAPS), and serves as adjunct graduate faculty to the University of North Texas Health Science Center in Fort Worth. Ms. Newman is also a 2005 Distinguished Alumni for the University of Texas at Arlington, and the former Chairman of the Board of Trustees for ACRP.
|
| Go To Top |
InVivo’s Scientific Advisory Board |
|
Bob Langer, Sc.D. - Scientific
Advisory Board |
Robert S. Langer is one of 14 Institute Professors (the highest honor
awarded to a faculty member) at the Massachusetts Institute of
Technology (MIT). Dr. Langer has written over 860 articles. He also has
over 500 issued or pending patents worldwide, one of which was cited as
the outstanding patent in Massachusetts in 1988 and one of 20
outstanding patents in the United States. Dr. Langer’s patents have
been licensed or sublicensed to over 100 pharmaceutical, chemical,
biotechnology and medical device companies; a number of these companies
were launched on the basis of these patent licenses. He served as a
member of the United States Food and Drug Administration’s SCIENCE
Board, the FDA’s highest advisory board, from 1995-2002 and as its
Chairman from 1999-2002.
Dr. Langer has received over 140 major awards. In 2002, he received the
Charles Stark Draper Prize, considered the equivalent of the Nobel
Prize for engineers and the world’s most prestigious engineering prize,
from the National Academy of Engineering. He is the also the only
engineer to receive the Gairdner Foundation International Award; 65
recipients of this award have subsequently received a Nobel Prize.
Among numerous other awards Langer has received are the Dickson Prize
for Science (2002), Heinz Award for Technology, Economy and Employment
(2003), the Harvey Prize (2003), the John Fritz Award (2003) (given
previously to inventors such as Thomas Edison and Orville Wright), the
General Motors Kettering Prize for Cancer Research (2004), the Dan
David Prize in Materials Science (2005) and the Albany Medical Center
Prize in Medicine and Biomedical Research (2005), the largest prize in
the U.S. for medical research. In 2006, he was inducted into the
National Inventors Hall of Fame. In 1998, he received the Lemelson-MIT
prize, the world’s largest prize for invention for being “one of
history’s most prolific inventors in medicine". In 1989 Dr. Langer was
elected to the Institute of Medicine of the National Academy of
Sciences, and in 1992 he was elected to both the National Academy of
Engineering and to the National Academy of Sciences. He is one of very
few people ever elected to all three United States National Academies
and the youngest in history (at age 43) to ever receive this
distinction.
Forbes Magazine (1999) and Bio World (1990) have named Langer as one of
the 25 most important individuals in biotechnology in the world.
Discover Magazine (2002) named him as one of the 20 most important
people in this area. Forbes Magazine (2002) selected Langer as one of
the 15 innovators world wide who will reinvent our future. Time
Magazine and CNN (2001) named Langer as one of the 100 most important
people in America and one of the 18 top people in science or medicine
in America. Parade Magazine (2004) selected Langer as one of 6 “Heroes
whose research may save your life.” He has served, at various times, on
15 boards of directors and 30 Scientific Advisory Boards of such
companies as Wyeth, Alkermes, Mitsubishi Pharmaceuticals,
Warner-Lambert, and Momenta Pharmaceuticals Dr. Langer has received
honorary doctorates from the ETH (Switzerland), the Technion (Israel),
the Hebrew University of Jerusalem (Israel), the Universite Catholique
de Louvain (Belgium), the University of Liverpool (England), the
University of Nottingham (England), Albany Medical College, the
Pennsylvania State University, Northwestern University and Uppsala
University (Sweden). He received his Bachelor’s Degree from Cornell
University in 1970 and his Sc.D. from the Massachusetts Institute of
Technology in 1974, both in Chemical Engineering.
|
| Go To Top |
| Richard Roberts, PhD: 1993 Nobel Laureate in Medicine and Physics |
| Eric Woodard, Scientific Advisory Board |
| Go To Top |
| Todd Albert, MD- Scientific Advisory Board |
Todd J. Albert, MD, is the James Edwards Professor and Chair of the Department of Orthopaedics at Jefferson Medical College in Philadelphia. He is also the President of the Rothman Institute in Philadelphia.
Previously, he served as Co-director of Reconstructive Spine Surgery and the Spine Fellowship Program at Thomas Jefferson University. Dr. Albert graduated magna cum laude from Amherst College, received his doctor of medicine degree from the University of Virginia School of Medicine, and completed a residency in Orthopaedic surgery at Thomas Jefferson University Hospital (where he was named Outstanding Chief Resident) and a fellowship in spinal surgery at the Minnesota Spine Center.
Dr. Albert serves on the boards of several scholarly journals, including Spine, The Spine Journal, and The Journal of Spinal Disorders and Techniques, as well as medical associations, including American Academy of Orthopaedic Surgery, Cervical Spine Research Society, Scoliosis Research Society, International Society for Study of the Lumbar Spine, and North American Spine Society. He is Chair of Network Development for the National Spine Network, a consortium of centers of excellence for spine care throughout the United States.
Dr. Albert has published over 200 scientific articles, authored over 40 book chapters, and presented his research both nationally and internationally. He has published seven textbooks on spinal surgery, including Spine Surgery: Tricks of the Trade; Surgical Approaches to the Spine; Master cases: Spine Surgery; Physical Examination of the Spine; and Spinal Deformities, The Essentials.
|
| Go To Top |
| Jonathan Slotkin, MD- Scientific Advisory Board |
Dr. Slotkin is a clinical neurosurgeon and research scientist.
Clinically, Dr. Slotkin has expertise in complex spinal surgery, minimally-invasive spinal surgery, spinal oncology surgery, and brain tumor surgery. Dr. Slotkin completed residency training in neurosurgery at Harvard Medical School, Brigham and Women’s Hospital. He is the co-editor of a two volume publication on spinal surgery. He is currently a clinical fellow in complex spinal surgery with Dr. Eric Woodard.
Dr. Slotkin’s research interests include regeneration and plasticity after spinal cord injury, and nanotechnology initiatives for cellular labeling and non-invasive cell tracking. Dr. Slotkin has authored or co-authored several peer-reviewed scientific publications in the areas of repair after spinal cord injury in animal models, and in vivo quantum dot labeling of neural stem cells. Dr. Slotkin has expertise in the application of nanotechnology research to clinical neurosurgery and neurology. His work was awarded the Apfelbaum Award for Research by the American Association of Neurological Surgeons. He is currently investigating stem cell and polymer scaffold repair of spinal cord injury and stroke in the laboratory of Dr. Ted Teng at Harvard Medical School. |
| Go To Top |
| Alex Vaccaro, MD- Scientific Advisory Board |
Dr. Alexander R. Vaccaro is Co-Director of the Delaware Valley Regional Spinal Cord Injury Center at Thomas Jefferson University, one of the largest referral programs for spinal injury in the country.
He also serves as Co-Director of Reconstructive Spine Services at the Rothman Institute and as Co-Director of the Spine Fellowship at Thomas Jefferson University. Dr. Vaccaro graduated summa cum laude from Boston College. He received his medical degree from Georgetown University School of Medicine, where he graduated cum laude. He performed his surgical internship at Cedars-Sinai Medical Center in Los Angeles. He then completed a residency in Orthopaedic surgery at Thomas Jefferson University Hospital and a spine fellowship at the University of California at San Diego.
Dr. Vaccaro has received numerous awards commending his outstanding and prolific research, and has published and presented extensively on his findings. He has served as moderator or chairman at over 80 national and international spine symposiums. His recent textbook, Principles and Practices of Spine Surgery (2002), is used as a standard for spine care nationally and internationally. He serves as a Professor in the Department of Orthopaedic Surgery at Jefferson Medical College of Thomas Jefferson University and is a member of numerous medical societies.
In 2002 he was selected to be an American Orthopaedic Association Japanese Traveling Fellow where he lectured at numerous academic universities in Japan. In the summer of 2003 he toured Europe as a Scoliosis Research Society traveling fellow participating in surgery and lecturing on spinal deformity. In 2004 he was selected to be the executive editor of Orthopaedic Knowledge Update (OKU) 8, the latest edition of the premier Orthopaedic review textbook.
|
| Go To Top |
| InVivo Business Advisory Board |
| Stan Lapidus, President & CEO of
Helicos Biosciences Corporation |
Mr. Lapidus is an experienced life-science entrepreneur. Helicos is his
third life-science start-up. In 1995 he founded EXACT Sciences
Corporation (NASDAQ: EXAS), an applied genomics company that develops
and markets non-invasive, DNA-based methods for early detection of
colorectal and other common cancers. He served as President from 1995
through 2000 and Chairman of EXACT Sciences' Board of Directors from
2000 through 2005. He continues to serve as a board member. Prior to
EXACT, Mr. Lapidus founded Cytyc Corporation (NASDAQ:CYTC) and was
President and CEO from 1987 through 1994. In addition to his
entrepreneurial activities, Mr. Lapidus holds academic appointments in
the Pathology Department at Tufts University Medical School and MIT's
Sloan School of Management. He earned a BSEE from Cooper Union. He has
served as a trustee of Cooper Union since 2002. Mr. Lapidus holds 29
issued patents. |
| Go To Top |
| Paul Mraz, Chief Executive Officer of CeraPedics, Inc |
Paul Mraz has been active in the Medical Device and Life Sciences Industry for over 17 years - in companies large and small, both venture backed and privately funded - with roles in executive management, product development, marketing, sales management and business development - all on a global basis.
Mr. Mraz currently serves as Chief Executive Officer of CeraPedics, Inc., a medical device company located outside Denver, CO. CeraPedics is working toward commercializing products for the orthopaedic bone graft substitutes market based on its proprietary small peptide technology and recently completed a $14.5M Series A financing with OrbiMed Advisors, LLC.
Mr. Mraz most recently served as Chairman and CEO of Angstrom Medica, Inc. (acquired by Pioneer Surgical Technology), a privately funded, early-stage biomaterials nanotechnology company engaged in the development of structural, calcium phosphate-based medical devices for the spinal, sports medicine, and trauma markets.
Prior to Angstrom Medica, Mr. Mraz was a Principal of Link Spine Group Inc., a start-up medical device company that developed and commercialized the world’s first total disc replacement for the lumbar spine. Mr. Mraz served as Vice President - Worldwide Marketing and International Sales until its acquisition by Johnson & Johnson in June 2003.
Mr. Mraz was also a key management team member of three other early-stage medical device companies and his early experience includes positions at Figgie Medical Systems, Ortho Development Corporation (acquired by Japan MDM) and Marlow Surgical Technologies, Inc. (acquired by Cooper Surgical) as well as DePuy, Inc. and DePuy Spine (formerly AcroMed Corporation) – both acquired by Johnson & Johnson in 1998.
Mr. Mraz also currently serves as a Director of superDimension, Ltd. (Herzliya, ISRAEL and Plymouth, MN), an emerging world leader in the minimally-invasive diagnosis and treatment of lung disease (e.g. cancer, emphysema) via interactive real-time guidance of endoscopic tools and bronchoscopy.
Mr. Mraz received a B.S. degree in Mechanical Engineering from Lafayette College and a M.S. degree in Mechanical Engineering and Biomechanics from Case Western Reserve University. Mr. Mraz holds six US Patents for various medical devices and is an active advisor to numerous venture capital groups. Mr. Mraz also enjoys mentoring and advising other entrepreneurs in the medical device industry worldwide.
|
| Go To Top |
| David Feigal, MD Sr. VP Global Regulatory Compliance Elan Corporation |
David W. Feigal Jr., MD, joined Elan as Senior Vice President, Head of
Global Regulatory and Global Safety Surveillance in November 2006.
Prior to joining Elan, David spent 12 years with the FDA. During his
time at the FDA he was Head of the Center for Devices for Five years
and he was also Head of the Center for Biologics for five years.
Before joining the FDA, Dr. Feigal worked for 10
years within the academic and hospital settings of the University of
California in San Diego, San Francisco and Davis. Dr. Feigal holds a BA
from University of Minnesota, an MD from Stanford University and a
Master of Public Health from the University of California, Berkeley.
|
| Go To Top |
| Dr. David Ellis Ph.D. |
Dr. Ellis was born in the United Kingdom, where he received a British
Petroleum scholarship to the University of St. Andrews. He earned an
Honors degree in Chemistry in 1964, followed by a Ph.D. in Biophysics
in 1967. After university, he joined 3i Group PLC, the largest private
equity manager in the world. After attending the Sloan School of MIT,
Dr. Ellis was selected to found and lead the team responsible for 3i’s
technology investments and turnaround investments, where he had
oversight of over 100 private equity investments.
From 1975 to 1981, David held
operational roles in the U.K. and
the U.S.:
-
COO and CEO of B.H. Blackwell
Ltd., the world’s largest
distributor of library
materials. Acquired its largest
competitor, Richard Abel &
Company (Portland, Oregon). -
CFO of Software Sciences
International Ltd., a computer
systems group specializing in
defense systems, air traffic
control and newspaper
automation. Orchestrated the
sale to BOC Group plc. -
CEO of Software Sciences Inc. In
the U.S. book industry, Dr.
Ellis introduced specialized
point-of-sale systems,
back-office inventory control
systems, and MIS systems, most
notably in association with the
Ingram Book Company.
In 1988, David and Sal Massaro launched the EGL investment business.
Based on David’s relationships in British finance circles, he raised
capital for U.S. venture investments, initially from Mercury Asset
Management (MAM), followed later by National Westminster Bank
(Natwest). EGL invested in a range of sectors, including information
technology, healthcare, instrumentation, manufacturing, and
distribution businesses at all stages of development. All investments
have been realized. David has also been active as an Angel investor
with current investments in Metabolic Testing Services (MTShealth.com),
The Gideon Group (thegideongroup.com) and SugarLoaf Products
(sugarloafproducts.com).
Dr. Ellis has been very active in the Atlanta technology community
since his arrival in 1979. He co-founded the MIT Enterprise Forum of
Atlanta and, in 1998, received the Georgia Technology Forum award for
“Outstanding Contribution to the Technology Industry.” He currently
serves on the advisory board of the College of Sciences at Georgia
Tech, as well as the advisory boards of the Shepherd Center and two
Rehabilitation Engineering Research Centers. David’s memberships
include the Technology Association of Georgia, the Technology Executive
Roundtable, the British-American Business Group, and the Atlanta
Venture Forum.
|
| Go To Top |
| Arnoldo Hax, Ph.D.- Alfred P Sloan
Professor of Management MIT-Sloan |
Arnoldo Hax is the Alfred P. Sloan Professor of Management at the Sloan
School of Management of the Massachusetts Institute of Technology. He
served as Deputy Dean of the Sloan School from 1987 through 1990. Prior
to joining MIT in 1972, Dr. Hax was a faculty member at the Harvard
Business School, and a senior consultant for Arthur D. Little, Inc.
He has published extensively in the fields of
strategic management, management control, operations management, and
operations research. He has authored and co-authored nine books,
including The Delta Project: Discovering New Sources of Profitability
in a Networked Economy with Dean Wilde, and about one hundred journal
articles. An accomplished educator, he won the MIT-Sloan School’s Salgo
Award for Excellence in Teaching. Dr. Hax has wide consulting experience and has
assisted many companies in developing formal strategic planning
processes, including Synthes, Synthes Spine, Advanced Micro Devices,
Eastman Chemical, Merck, EDS, Saturn, Coca-Cola, Digital Equipment
Corporation, Motorola, General Motors, Citibank, Prime Computer,
Searle, Analog Devices, Westinghouse Electric, Unilever, 3M, and Brown
Boveri (Switzerland). Dr. Hax is former Chairman of the Board of Sloan
Management Review. In addition he is Strategic Management Editor for
Interfaces and former editor of Operations Research, and Naval Research
Logistics Quarterly. He is on the editorial board of the Journal of
Manufacturing and Operations Research and the Journal of High
Technology Management Research. He has been granted a Dean’s Award for
Excellence at the Sloan School of Management and has been listed in
Who’s Who in Science and Technology.
|
| Go To Top |
|
| TERMS
OF USE |
| |
PRIVACY
POLICY |
| |
COPYRIGHT
@ ---- INVIVO |
|
|